title: Gestational valproate alters BOLD activation in response to complex social and primary sensory stimuli.
abstract: Valproic acid (VPA) has been used clinically as an anticonvulsant medication during pregnancy; however, it poses a neurodevelopmental risk due to its high teratogenicity. We hypothesized that midgestational (GD) exposure to VPA will lead to lasting deficits in social behavior and the processing of social stimuli. To test this, animals were given a single IP injection of 600 mg/kg of VPA on GD 12.5. Starting on postnatal day 2 (PND2), animals were examined for physical and behavior abnormalities. Functional MRI studies were carried out after PND60. VPA and control animals were given vehicle or a central infusion of a V(1a) antagonist 90 minutes before imaging. During imaging sessions, rats were presented with a juvenile test male followed by a primary visual stimulus (2 Hz pulsed light) to examine the effects of prenatal VPA on neural processing. VPA rats showed greater increases in BOLD signal response to the social stimulus compared to controls in the temporal cortex, thalamus, midbrain and the hypothalamus. Blocking the V(1a) receptor reduced the BOLD response in VPA animals only. Neural responses to the visual stimulus, however, were lower in VPA animals. Blockade with the V(1a) antagonist did not revert this latter effect. Our data suggest that prenatal VPA affects the processing of social stimuli and perhaps social memory, partly through a mechanism that may involve vasopressin V(1a) neurotransmission.
authors.affiliation: Department of Psychology, Northeastern University, Boston, Massachusetts, United States of America.
authors.forename: Ada C
authors.initials: AC
authors.lastname: Felix-Ortiz
authors.forename: Marcelo
authors.initials: M
authors.lastname: Febo
mesh_terms: D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D001127:Arginine Vasopressin / Q000031:analogs & derivatives / Q000187:drug effects / Q000494:pharmacology / Q000502:physiology; D001522:Behavior, Animal / Q000187:drug effects*; D005260:Female; D008279:Magnetic Resonance Imaging; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D010100:Oxygen / Q000097:blood*; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D051381:Rats; D012919:Social Behavior; D014635:Valproic Acid / Q000494:pharmacology*; D014785:Vision, Ocular / Q000187:drug effects / Q000502:physiology; D014828:Vocalization, Animal / Q000187:drug effects
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D001127:Arginine Vasopressin; D014635:Valproic Acid; C025043:vasopressin, 1-(1-mercaptocyclohexaneacetic acid)-2-(O- methyl-L-tyrosine)-8-L-arginine-; D010100:Oxygen